Accelerated epirubicin-ifosfamide-dacarbazine regimen in patients with adult soft tissue sarcomas

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 19, Issue 1, 1996, Pages 78-81

  Michelotti, Andrea ^a   Romanini, Antonella ^a   Giannessi, Piergiorgio ^a   Bengala, Carmelo ^a   Conte, Pierfranco ^a,b  

^a UNIVERSITY OF PISA   (Italy)

^b SANTA CHIARA HOSPITAL   (Italy)

Author keywords

Accelerated treatment; G CSF; Soft tissue sarcomas

Indexed keywords

DACARBAZINE; EPIRUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; HUMAN; INFECTION RISK; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE COUNT; NEUTROPENIA; ORAL DRUG ADMINISTRATION; SOFT TISSUE SARCOMA; SUBCUTANEOUS DRUG ADMINISTRATION;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DACARBAZINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; IFOSFAMIDE; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUTROPENIA; SARCOMA; TREATMENT OUTCOME;

EID: 0029670628     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199602000-00016     Document Type: Article

References (22)

1. Silverberg E, Lubera J. Cancer statistics. Ca 1988;38:5-22.
2. Elias A, Ryan L, Sulkes A, et al. Response to doxorubicin, ifosfamide and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J Clin Oncol 1989;7:1208-16.
3. Casali P, Pastorino U, Santoro A, et al. Epirubicin, ifosfamide and dacarbazine (EID) combined with surgery in advanced soft tissue sarcomas. Proc Am Soc Clin Oncol 1991;10:353.
4. Bronchud MH, Scarffe JH, Thacher N, et al. Phase I/II study of recombinant human granulocyte colony stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer 1987;56:804-12.
5. Gabrilove JL, Jakubowski A, Fain K, et al. A phase-I study of granulocyte colony stimulating factor in patients with transitional cell carcinoma of the urothelium. J Clin Invest 1988;82:1554-61.
6. Gabrilove JL, Jakubowski A, Sher H, et al. Granulocyte colony stimulating factor reduces neutropenia and associated morbidity of chemotherapy for transitional cell carcinoma of urothelium. N Engl J Med 1988;318:1414-22.
7. Morstyn G, Souza LM, Keech J, et al. Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet 1988;1:6667-71.
8. Hryniuk WM. The importance of dose-intensity in the outcome of chemotherapy. In: Devita VT, Hellman S, Rosemberg SA, eds. Important advances in oncology. Philadelphia: Lippincott; 1988;121-42.
9. Coppin CML. The description of chemotherapy delivery: options and pitfalls. Semin Oncol 1987;14(suppl 4):34-42.
10. Longo DL, Duffey PL. DeVita VT Jr, et al. The calculation of actual or received dose intensity: a comparison of published methods. J Clin Oncol 1991;9:2042-51.
11. WHO Handbook for reporting results of cancer treatment. Geneva, Switzerland: World Health Organization, 1979.
12. Antman KH, Ryan L, Elias A, et al. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. J Clin Oncol 1989;7:126-31.
13. Borden EC, Amato DA, Edmondson JH, et al. Randomized comparison of doxorubicin and vindesine to doxorubicin for patients with metastatic soft-tissue sarcomas. Cancer 1991;66: 862-7.
14. Edmondson J, Blum R, Ryan L, et al. Phase II Eastern Cooperative Oncology Group study of ifosfamide + doxorubicin versus mitomycin + doxorubicin + cisplatin versus doxorubicin alone against advanced soft tissue sarcomas. Proc Am Soc Clin Oncol 1991;10:352.
15. Gottlieb JA, Benjamin RS, Baker LH, et al. Role of DTIC (NSC-45388) in the chemotherapy of sarcomas. Cancer Chemother Rep 1976;60:199-203.
16. O'Bryan RM, Baker LH, Gottlieb JE, et al. Dose response evaluation of Adriamycin in human neoplasia. Cancer 1977;39: 1940-8.
17. Antman K, Baker L, Balcerzak S, et al. An intergroup (SWOG&CALGB) phase III randomized study of doxorubicin with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. Proc Am Soc Clin Oncol 1990;9:311.
18. Baker LH, Frank J, Fine G, et al. Combination chemotherapy using adriamycin, DTIC, cyclophosphamide and actinomicyn D for advanced soft-tissue sarcomas: a randomized comparative trial - a phase III Southwest Oncology Group study (7613). J Clin Oncol 1987;5:851-61.
19. Coldman AJ, Goldie JH. Impact of dose intense chemotherapy on the development of permanent drug resistance. Semin Oncol 1987;14:29-33.
20. Steward WP, Verweij R, Somerts D, et al. Granulocyte macrophage colony stimulating factor allows safe escalation of dose intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer: Soft Tissue and Bone Sarcomas Group. J Clin Oncol 1993;11:15-21.
21. Chevalier B, Bui NB, Bonichon F, et al. Efficacy of rG-CSF on hematological tolerance to MAID chemotherapy in sarcoma patients and impact on dose intensity. Proc Am Soc Clin Oncol 1992;11:412.
22. Chevreau C, Bui BN, Chevalier B, et al. Phase I-II trial of intensification of the MAID regimen with recombinant human granulocyte colony stimulating factor (rG-CSF) in patients suffering from advanced soft tissue sarcoma (STS). Proc Am Soc Clin Oncol 1992;11:412.